FilingReader Intelligence
Fosun Pharma subsidiary licenses drug globally for $120m
August 11, 2025 at 09:29 AM UTC•By FilingReader AI
Fosun Pharma Industrial granted Expedition exclusive global rights (excluding China, Hong Kong, and Macao) to develop and commercialize XH-S004.
The deal includes upfront and milestone payments of up to $120 million, with $17 million paid initially. Potential sales-based milestones could reach $52.5 million, plus royalties.
XH-S004 is currently in Phase II and Ib clinical trials in China.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SSE:600196•Shanghai Stock Exchange
PharmaceuticalsShanghai Blue Chip
News Alerts
Get instant email alerts when Shanghai Fosun Pharmaceutical Group publishes news
Free account required • Unsubscribe anytime